Chemical modification of epibatidine causes a switch from agonist to antagonist and modifies its selectivity for neuronal nicotinic acetylcholine receptors

被引:37
作者
Spang, JE
Bertrand, S
Westera, G [1 ]
Patt, JT
Schubiger, PA
Bertrand, D
机构
[1] Swiss Fed Inst Technol, Ctr Radiopharmaceut Sci, Zurich, Switzerland
[2] Paul Scherrer Inst, Villigen, Switzerland
[3] Univ Zurich Hosp, Dept Radiol, CH-8091 Zurich, Switzerland
[4] Univ Zurich Hosp, Clin Nucl Med, CH-8091 Zurich, Switzerland
[5] Ctr Med Univ Geneva, Dept Physiol, CH-1211 Geneva, Switzerland
来源
CHEMISTRY & BIOLOGY | 2000年 / 7卷 / 07期
关键词
acetylcholine receptors; epibatidine analogues; nAChR; neuronal nicotinic receptors;
D O I
10.1016/S1074-5521(00)00138-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Studies of ligand gated channels strongly rely on the availability of compounds that can activate or inhibit with high selectivity one set or a subset of defined receptors. The alkaloid epibatidine (EPB), originally isolated from the skin of an Ecuadorian poison frog, is a very specific agonist for the neuronal nicotinic acetylcholine receptors (nAChRs). We used EPB derivatives to investigate the pharmacophore of nAChR subtypes. Results: Optically pure enantiomers of EPB analogues were synthesised. Analogues were obtained altered in the aromatic part: the chlorine was eliminated and the relative position of the pyridyl nitrogen changed. Voltage clamp electrophysiology was performed with these compounds on neuronal nAChRs reconstituted in Xenopus oocytes. The EPB derivatives show different activities towards the various nAChR subtypes. Conclusions: Small changes in the molecular structure of EPB produce marked changes in its capacity to activate the nAChRs. Subtype specificity can be obtained by changing the position of or by eliminating the pyridyl nitrogen.
引用
收藏
页码:545 / 555
页数:11
相关论文
共 67 条
[1]  
ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666
[2]   Choline is a selective agonist of α7 nicotnic acetylcholine receptors in the rat brain neurons [J].
Alkondon, M ;
Pereira, EFR ;
Cortes, WS ;
Maelicke, A ;
Albuquerque, EX .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1997, 9 (12) :2734-2742
[3]  
ALKONDON M, 1995, J PHARMACOL EXP THER, V274, P771
[4]  
ANTONOV SM, 1995, MOL PHARMACOL, V47, P558
[5]   Synthesis and nicotinic activity of epiboxidine: An isoxazole analogue of epibatidine [J].
Badio, B ;
Garraffo, HM ;
Plummer, CV ;
Padgett, WL ;
Daly, JW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 321 (02) :189-194
[6]  
BADIO B, 1994, MOL PHARMACOL, V45, P563
[7]   ANTINOCICEPTIVE EFFECTS OF THE ALKALOID EPIBATIDINE - FURTHER-STUDIES ON INVOLVEMENT OF NICOTINIC RECEPTORS [J].
BADIO, B ;
SHI, D ;
GARRAFFO, HM ;
DALY, JW .
DRUG DEVELOPMENT RESEARCH, 1995, 36 (01) :46-59
[8]  
BADIO B, 1994, MED CHEM RES, V4, P440
[9]   Synthesis of (+/-)-epibatidine and its analogues [J].
Bai, DG ;
Xu, R ;
Chu, GH ;
Zhu, XG .
JOURNAL OF ORGANIC CHEMISTRY, 1996, 61 (14) :4600-4606
[10]  
Bai Donglu, 1997, Drugs of the Future, V22, P1210